Lung Cancer News and Research

Latest Lung Cancer News and Research

Cyclacel Pharmaceuticals reports net loss of $5.1M for first-quarter 2010

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the first quarter ended March 31, 2010.

14 May 2010

Researchers to discuss various implications for personalized medicine during one-day symposium

On May 27, researchers with the National Human Genome Research Institute and the National Cancer Institute, along with Group Health Cooperative in Seattle and Henry Ford Health System, will debate and discuss that question during the one-day symposium "Multiplex Initiative: Implications for Personalized Medicine."

13 May 2010

Researchers develop new approach to immunotherapy of cancer

Harnessing the immune system is emerging as one of the most promising new ways to fight cancer. Most cancer cells are eliminated by the immune system; however, over a lifetime, a few may escape this immune surveillance and lead to tumors and metastases. Hence a formidable opportunity has been to find ways to make the immune system recognize the tumor as a foreign body and trigger a response.

13 May 2010

OXiGENE reports consolidated net loss of $11.0M for first-quarter 2010

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ended March 31, 2010, and presented an update on recent clinical and corporate progress.

12 May 2010

Allergic conditions that result from hyper reactive immune system may lower cancer risk: Study

If you have asthma or eczema, your hyper reactive immune system may lower your risk of some of the most common types of cancer, according to a study published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology.

12 May 2010

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the first quarter ended March 31, 2010.

11 May 2010

Research may aid in developing new cancer therapies

Immortality and uncontrolled cell division are the fundamental differences between cancer cells and normal cells.

11 May 2010

FDA grants EUA for IQuum's Liat Influenza A/2009 H1N1 Assay

IQuum, Inc. today announced it has been granted an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Liat™ Influenza A/2009 H1N1 Assay. The assay detects and differentiates 2009 H1N1 influenza viral RNA starting from collected nasopharyngeal swab samples in less than 30 minutes.

10 May 2010

QRxPharma reports successful outcome of Phase 1 trial for MoxDuo CR for chronic pain

QRxPharma announced today the successful outcome of a Phase 1 trial for MoxDuo CR, a controlled-release (CR) Dual-Opioid(TM) designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic). The purpose of the trial was to determine which of the various experimental formulations provided the optimum duration of drug levels in the blood.

10 May 2010

Asthmatx announces first U.S. patient treated with BT delivered by Alair System

Asthmatx, Inc. reported today that doctors at Virginia Hospital Center in Arlington, Va., recently treated the first U.S. patient with bronchial thermoplasty (BT) delivered by the Alair® System, the first device-based asthma treatment approved by the U.S. Food and Drug Administration (FDA).

10 May 2010

MicroStockProfit.com features investment report on ARIAD Pharmaceuticals

MicroStockProfit.com announces an investment report featuring ARIAD Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

10 May 2010

UT Southwestern offers advanced lung-cancer patients free screenings of tumors for genetic mutations

UT Southwestern Medical Center is the only site in North Texas participating in a national study that offers advanced lung-cancer patients free screenings of their tumors for genetic mutations, some of which might be targets for treatment with existing or experimental therapies.

10 May 2010

Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin

New research by scientists at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute suggests that a drug currently approved to treat erectile dysfunction may significantly enhance the delivery of the anti-cancer drug Herceptin to certain hard-to-treat brain tumors.

10 May 2010

Minimally invasive scopes to detect cancer

Just as cameras and televisions have been reinvented in the last decade with improved optics, sharpness and brightness, so have the tiny imaging scopes that physicians use to peer into the body's nooks and crannies -- its organs and digestive system.

7 May 2010

ADDF awards $210,300 to Amicus Therapeutics to evaluate PCs for treating Alzheimer's disease

The Alzheimer's Drug Discovery Foundation announced today that it has awarded a grant of $210,300 to Amicus Therapeutics (Cranbury, NJ) to evaluate small-molecule, orally delivered pharmacological chaperone compounds as a novel approach for treating Alzheimer's disease.

7 May 2010

Telik first-quarter net loss decreases to $5.3 million

Telik, Inc. today reported financial results for the first quarter ended March 31, 2010. The net loss for the quarter ended March 31, 2010 was $5.3 million, or $0.10 per share, compared with a net loss of $7.7 million, or $0.14 per share, for the same period in 2009.

7 May 2010

Australia’s first ever health policy for men

Prime Minister Kevin Rudd yesterday announced Australia’s first ever men’s health policy called the “National Male Health Policy”. He said in the announcement during a visit to the Whittlesea Men's Shed in Victoria, “They either think that they're invincible that they can just tough it out…'They don't like talking about it usually, and frankly, the problem with all that is it makes it really hard to deal with men's health problems before they become too serious.” He felt this move was long due. He added, “'It's a pretty important time that we do that, we're probably about 110 years late.”

6 May 2010

Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million

Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.

6 May 2010

ArQule reports net loss of $9,752,000 for first-quarter 2010

ArQule, Inc. today announced its financial results for the first quarter of 2010.

6 May 2010

Study aims to clarify expression patterns of CD24 in NSCLC

The May edition of the Journal of Thoracic Oncology features a study aimed to clarify expression patterns of a novel cancer biomarker, CD24, in non-small cell lung carcinomas (NSCLC) and to correlate the findings to clinicopathologic variables, such as performance status, age, gender and prognostic significance.

6 May 2010